If proven to reduce the incidence of BRCA1/2-related carcinomas in clinical trials, the repurposing of a bone-targeted agent such as denosumab for oncology indications might inaugurate a new era of molecularly targeted pharmacological cancer prevention therapies and perhaps cancer treatments using RANKL inhibitors for millions of people worldwide [7]. Here, TNFSF11 is linked to cancer.